title: Survival and prognosis after pneumonectomy for lung cancer in the elderly.
abstract: BACKGROUND
  The number of elderly patients with lung cancer is increasing. This study was undertaken to assess the validity of pneumonectomy for the treatment of lung cancer in this patient group.
  
  
  METHODS
  Twenty-seven patients 70 years old or older (elderly group) and 95 patients younger than 70 years (younger group) who underwent pneumonectomy between January 1985 and March 1996 formed the study group. In the elderly group, 22 patients had squamous cell carcinoma, 2 had adenocarcinoma and 3, small cell carcinoma; 1 patient was in postoperative stage I, 4 patients were in stage II, 14 in stage IIIA, 5 in stage IIIB, and 3 in stage IV of the disease. The only significant differences in patient characteristics between the two groups were the percentage of patients undergoing right pneumonectomy and the percentage of patients receiving chemotherapy or radiotherapy within 3 months before or after operation or both times.
  
  
  RESULTS
  The prognosis for the elderly group was comparable to that of the younger group for all stages of the disease; the overall 5-year survival rate was 30.5% for the younger group and 11.5% for the elderly group. However, operation-associated mortality was significantly higher in the elderly group (22.2% versus 3.2%; p < 0.005). The prognosis was better for patients with a centrally located tumor than a peripheral tumor in both groups [13.5% versus 2.0% in the elderly group and 46.7% versus 5.2% (p < 0.01) in the younger group] and significantly better for patients having a left pneumonectomy than a right pneumonectomy in the younger group (46.7% versus 5.2%; p < 0.01) but not in the elderly group (13.7% versus 22.2%). Adjuvant treatment did not have any beneficial effect on the prognosis in either group.
  
  
  CONCLUSIONS
  Pneumonectomy for lung cancer in elderly patients appears to be justified because the outcome in our study was comparable with that for the younger patients. However, it should be performed only in carefully selected patients because of the increased operative risk.
authors.affiliation: First Department of Internal Medicine, Toyama Medical and Pharmaceutical University, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Mizushima
authors.forename: H
authors.initials: H
authors.lastname: Noto
authors.forename: S
authors.initials: S
authors.lastname: Sugiyama
authors.forename: Y
authors.initials: Y
authors.lastname: Kusajima
authors.forename: R
authors.initials: R
authors.lastname: Yamashita
authors.forename: T
authors.initials: T
authors.lastname: Kashii
authors.forename: M
authors.initials: M
authors.lastname: Kobayashi
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000601:surgery; D000367:Age Factors; D000368:Aged; D018288:Carcinoma, Small Cell / Q000401:mortality / Q000601:surgery; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000601:surgery; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality* / Q000503:physiopathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D011013:Pneumonectomy; D011379:Prognosis; D012129:Respiratory Function Tests; D016019:Survival Analysis